Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.08.326 on June 6 2005

Journal of Clinical Oncology, Vol 23, No 23 (August 10), 2005: pp. 5323-5333
© 2005 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baselga, J.
Right arrow Articles by Rojo, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baselga, J.
Right arrow Articles by Rojo, F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer

José Baselga, Joan Albanell, Amparo Ruiz, Ana Lluch, Pere Gascón, Vicente Guillém, Sonia González, Silvia Sauleda, Irene Marimón, Josep M. Tabernero, Maria T. Koehler, Federico Rojo

From the Vall d'Hebron University Hospital; Hospital Clinic, Barcelona; Instituto Valenciano de Oncologia; Universitat de Valencia, Hospital Clínico Universitario de Valencia and CESAT Valencia, Spain; and AstraZeneca, Wilmington, DE

Address reprint requests to José Baselga, MD, Chairman and Professor of Medicine, Medical Oncology Service, Vall d'Hebron University Hospital, P. Vall d'Hebron 119-129 08035 Barcelona, Spain; e-mail: jbaselga{at}vhebron.net.

PURPOSE: To evaluate the antitumor activity and pharmacodynamic/biologic effect of gefitinib 500 mg/day monotherapy in patients with previously treated, advanced breast cancer.

METHODS: In this phase II multicenter trial, the primary objective was assessment of the tumor response rate with gefitinib; secondary objectives included analysis of the pharmacodynamic and biologic profiles in healthy and tumor tissue.

RESULTS: Of 31 assessable patients, 12 (38.7%) had stable disease, including 3 (9.7%) with recurrent breast cancer that stabilized for ≥ 6 months. No complete or partial responses were observed. Pretreatment tumor samples were available in all patients. In addition, paired baseline and on-treatment (day 28) assessable skin and tumor biopsies were available in 27 and 16 patients, respectively. Sequential immunohistochemical studies in skin and tumor biopsies demonstrated complete inhibition of epidermal growth factor receptor (EGFR) phosphorylation in both healthy and malignant tissues. The downstream consequences of receptor blockade were distinct in skin and tumor samples: while phosphorylation of mitogen-activated protein kinase was inhibited in both tissues, gefitinib treatment induced p27 and a decrease in Ki67 in skin but not in tumors. Furthermore, gefitinib did not inhibit the activated form of Akt in the tumors.

CONCLUSION: This study demonstrates a good correlation between the degree of inhibition of EGFR in skin and in breast tumors. The lack of significant clinical activity of gefitinib in our study population is not due to lack of receptor inhibition in these tumors but rather to lack of EGFR dependence in the tested population.

Terms in blue are defined in the glossary, found at the end of this issue and online at www.jco.org.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. D. Green, P. A. Francis, V. Gebski, V. Harvey, C. Karapetis, A. Chan, R. Snyder, A. Fong, R. Basser, J. F. Forbes, et al.
Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer
Ann. Onc., November 1, 2009; 20(11): 1813 - 1817.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Zhang, T. A. LaFortune, S. Krishnamurthy, F. J. Esteva, M. Cristofanilli, P. Liu, A. Lucci, B. Singh, M.-C. Hung, G. N. Hortobagyi, et al.
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer
Clin. Cancer Res., November 1, 2009; 15(21): 6639 - 6648.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. A. Burris III, C. W. Taylor, S. F. Jones, K. M. Koch, M. J. Versola, N. Arya, R. A. Fleming, D. A. Smith, L. Pandite, N. Spector, et al.
A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies
Clin. Cancer Res., November 1, 2009; 15(21): 6702 - 6708.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
N. Normanno, A. Morabito, A. De Luca, M. C. Piccirillo, M. Gallo, M. R Maiello, and F. Perrone
Target-based therapies in breast cancer: current status and future perspectives
Endocr. Relat. Cancer, September 1, 2009; 16(3): 675 - 702.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. S. Finn, M. F. Press, J. Dering, M. Arbushites, M. Koehler, C. Oliva, L. S. Williams, and A. Di Leo
Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
J. Clin. Oncol., August 20, 2009; 27(24): 3908 - 3915.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. Kataoka, T. Mukohara, H. Shimada, N. Saijo, M. Hirai, and H. Minami
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
Ann. Onc., July 24, 2009; (2009) mdp304v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Di Leo, H. L. Gomez, Z. Aziz, Z. Zvirbule, J. Bines, M. C. Arbushites, S. F. Guerrera, M. Koehler, C. Oliva, S. H. Stein, et al.
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
J. Clin. Oncol., December 1, 2008; 26(34): 5544 - 5552.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. F. Press, R. S. Finn, D. Cameron, A. Di Leo, C. E. Geyer, I. E. Villalobos, A. Santiago, R. Guzman, A. Gasparyan, Y. Ma, et al.
HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
Clin. Cancer Res., December 1, 2008; 14(23): 7861 - 7870.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. N. Dickler, H. S. Rugo, C. A. Eberle, E. Brogi, J. F. Caravelli, K. S. Panageas, J. Boyd, B. Yeh, D. E. Lake, C. T. Dang, et al.
A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
Clin. Cancer Res., December 1, 2008; 14(23): 7878 - 7883.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L. Arteaga, A. O'Neill, S. L. Moulder, M. Pins, J. A. Sparano, G. W. Sledge, and N. E. Davidson
A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
Clin. Cancer Res., October 1, 2008; 14(19): 6277 - 6283.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Laheru, G. Croghan, R. Bukowski, M. Rudek, W. Messersmith, C. Erlichman, R. Pelley, A. Jimeno, R. Donehower, J. Boni, et al.
A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer
Clin. Cancer Res., September 1, 2008; 14(17): 5602 - 5609.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. L. Gomez, D. C. Doval, M. A. Chavez, P. C.-S. Ang, Z. Aziz, S. Nag, C. Ng, S. X. Franco, L. W.C. Chow, M. C. Arbushites, et al.
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer
J. Clin. Oncol., June 20, 2008; 26(18): 2999 - 3005.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Felip, F. Rojo, M. Reck, A. Heller, B. Klughammer, G. Sala, S. Cedres, S. Peralta, H. Maacke, D. Foernzler, et al.
A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy
Clin. Cancer Res., June 15, 2008; 14(12): 3867 - 3874.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
R A Walker
Immunohistochemical markers as predictive tools for breast cancer
J. Clin. Pathol., June 1, 2008; 61(6): 689 - 696.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Ren, B. Korchin, Q.-S. Zhu, C. Wei, A. Dicker, J. Heymach, A. Lazar, R. E. Pollock, and D. Lev
Epidermal Growth Factor Receptor Blockade in Combination with Conventional Chemotherapy Inhibits Soft Tissue Sarcoma Cell Growth In vitro and In vivo
Clin. Cancer Res., May 1, 2008; 14(9): 2785 - 2795.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
M. Scaltriti and J. Baselga
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 91 - 98.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. A. Lubet, E. Szabo, K. Christov, A. M. Bode, M. E. Ericson, V. E. Steele, M. M. Juliana, and C. J. Grubbs
Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes
Mol. Cancer Ther., April 1, 2008; 7(4): 972 - 979.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Petrelli, M. Cabiddu, M. E. Cazzaniga, M. Cremonesi, and S. Barni
Targeted Therapies for the Treatment of Breast Cancer in the Post-trastuzumab Era
Oncologist, April 1, 2008; 13(4): 373 - 381.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. H. El-Maraghi and E. A. Eisenhauer
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
J. Clin. Oncol., March 10, 2008; 26(8): 1346 - 1354.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Guix, N. de Matos Granja, I. Meszoely, T. B. Adkins, B. M. Wieman, K. E. Frierson, V. Sanchez, M. E. Sanders, A. M. Grau, I. A. Mayer, et al.
Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor-Positive Breast Cancers
J. Clin. Oncol., February 20, 2008; 26(6): 897 - 906.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Andre, R. Nahta, R. Conforti, T. Boulet, M. Aziz, L. X. H. Yuan, F. Meslin, M. Spielmann, G. Tomasic, L. Pusztai, et al.
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
Ann. Onc., February 1, 2008; 19(2): 315 - 320.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens
Application of PET/CT in the Development of Novel Anticancer Drugs
Oncologist, January 1, 2008; 13(1): 25 - 38.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Loprevite, M. Tiseo, M. Chiaramondia, M. Capelletti, C. Bozzetti, B. Bortesi, N. Naldi, R. Nizzoli, P. Dadati, A. Kunkl, et al.
Buccal Mucosa Cells as In vivo Model to Evaluate Gefitinib Activity in Patients with Advanced Non Small Cell Lung Cancer
Clin. Cancer Res., November 1, 2007; 13(21): 6518 - 6526.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Morabito, M. C. Piccirillo, K. Monaco, C. Pacilio, F. Nuzzo, P. Chiodini, C. Gallo, A. de Matteis, F. Perrone, and NCI Naples Breast Cancer Group
First-Line Chemotherapy for HER-2 Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment
Oncologist, November 1, 2007; 12(11): 1288 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Y. Nieto, F. Nawaz, R. B. Jones, E. J. Shpall, and S. Nawaz
Prognostic Significance of Overexpression and Phosphorylation of Epidermal Growth Factor Receptor (EGFR) and the Presence of Truncated EGFRvIII in Locoregionally Advanced Breast Cancer
J. Clin. Oncol., October 1, 2007; 25(28): 4405 - 4413.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. E. Smith, G. Walsh, A. Skene, A. Llombart, J. I. Mayordomo, S. Detre, J. Salter, E. Clark, P. Magill, and M. Dowsett
A Phase II Placebo-Controlled Trial of Neoadjuvant Anastrozole Alone or With Gefitinib in Early Breast Cancer
J. Clin. Oncol., September 1, 2007; 25(25): 3816 - 3822.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
K. To, Y. Zhao, H. Jiang, K. Hu, M. Wang, J. Wu, C. Lee, D. W. Yokom, A. L. Stratford, U. Klinge, et al.
The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) Prevents Y-Box Binding Protein-1 from Inducing Epidermal Growth Factor Receptor
Mol. Pharmacol., September 1, 2007; 72(3): 641 - 652.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Molinolo, S. M. Hewitt, P. Amornphimoltham, S. Keelawat, S. Rangdaeng, A. Meneses Garcia, A. R. Raimondi, R. Jufe, M. Itoiz, Y. Gao, et al.
Dissecting the Akt/Mammalian Target of Rapamycin Signaling Network: Emerging Results from the Head and Neck Cancer Tissue Array Initiative
Clin. Cancer Res., September 1, 2007; 13(17): 4964 - 4973.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
F. Yamasaki, D. Zhang, C. Bartholomeusz, T. Sudo, G. N. Hortobagyi, K. Kurisu, and N. T. Ueno
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity
Mol. Cancer Ther., August 1, 2007; 6(8): 2168 - 2177.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Yamasaki, M. J. Johansen, D. Zhang, S. Krishnamurthy, E. Felix, C. Bartholomeusz, R. J. Aguilar, K. Kurisu, G. B. Mills, G. N. Hortobagyi, et al.
Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt
Cancer Res., June 15, 2007; 67(12): 5779 - 5788.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. Tabernero
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents
Mol. Cancer Res., March 1, 2007; 5(3): 203 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L. Arteaga
Will Single-Time Tumor Profiling and a "Guilt by Association" Approach Allow Us to Outsmart HER2-Positive Breast Cancer?
Clin. Cancer Res., February 15, 2007; 13(4): 1071 - 1073.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Rubio-Viqueira, H. Mezzadra, M. E. Nielsen, A. Jimeno, X. Zhang, C. Iacobuzio-Donahue, A. Maitra, M. Hidalgo, and S. Altiok
Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays
Mol. Cancer Ther., February 1, 2007; 6(2): 515 - 523.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Rojo, L. Najera, J. Lirola, J. Jimenez, M. Guzman, M. D. Sabadell, J. Baselga, and S. R. y Cajal
4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and Prognosis
Clin. Cancer Res., January 1, 2007; 13(1): 81 - 89.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Rosell, M. Taron, N. Reguart, D. Isla, and T. Moran
Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway
Clin. Cancer Res., December 15, 2006; 12(24): 7222 - 7231.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. F. El-Rayes, S. Ali, I. F. Ali, P. A. Philip, J. Abbruzzese, and F. H. Sarkar
Potentiation of the Effect of Erlotinib by Genistein in Pancreatic Cancer: The Role of Akt and Nuclear Factor-{kappa}B
Cancer Res., November 1, 2006; 66(21): 10553 - 10559.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
C. Catania, T. M. De Pas, G. Pelosi, M. Manzotti, L. Adamoli, F. Nole, and A. Goldhirsch
Erlotinib-Induced Breast Cancer Regression
Ann. Pharmacother., November 1, 2006; 40(11): 2043 - 2047.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. R. Helft and C. K. Daugherty
Are We Taking Without Giving in Return? The Ethics of Research-Related Biopsies and the Benefits of Clinical Trial Participation
J. Clin. Oncol., October 20, 2006; 24(30): 4793 - 4795.
[Full Text] [PDF]

Home page
 JCOHome page
M. Agulnik, A. M. Oza, G. R. Pond, and L. L. Siu
Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents
J. Clin. Oncol., October 20, 2006; 24(30): 4801 - 4807.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Scaltriti and J. Baselga
The epidermal growth factor receptor pathway: a model for targeted therapy.
Clin. Cancer Res., September 15, 2006; 12(18): 5268 - 5272.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Rojo, J. Tabernero, J. Albanell, E. Van Cutsem, A. Ohtsu, T. Doi, W. Koizumi, K. Shirao, H. Takiuchi, S. R. Cajal, et al.
Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma
J. Clin. Oncol., September 10, 2006; 24(26): 4309 - 4316.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. A. Weber
Positron Emission Tomography As an Imaging Biomarker
J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. A. Weber
Chaperoning Drug Development with PET
J. Nucl. Med., May 1, 2006; 47(5): 735 - 737.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. Reusch, M. Sundaram, P. A. Davol, S. D. Olson, J. B. Davis, K. Demel, J. Nissim, R. Rathore, P. Y. Liu, and L. G. Lum
Anti-CD3 x Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers In vitro and in an Animal Model
Clin. Cancer Res., January 1, 2006; 12(1): 183 - 190.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. E. Bates and T. Fojo
Epidermal Growth Factor Receptor Inhibitors: A Moving Target?
Clin. Cancer Res., October 15, 2005; 11(20): 7203 - 7205.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online